Soluble CD23 in cerebrospinal fluid

A marker of AIDS-related non-Hodgkin's lymphoma in the brain

Simona Bossolasco, Anna Nilsson, Angelo De Milito, Adriano Lazzarin, Annika Linde, Paola Cinque, Francesca Chiodi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: AIDS-related non-Hodgkin's lymphoma (NHL) includes systemic lymphomas, often with brain involvement, and primary central nervous system (CNS) lymphomas. Objective: To examine if measurement of soluble CD23 (sCD23) in cerebrospinal fluid (CSF) is useful in the diagnosis and follow-up of AIDS-related NHL. Method: sCD23 was measured by enzyme-linked immunosorbent assay and EBV DNA by nested polymerase chain reaction for a group of 134 patients. The NHL group included 14 patients with primary HIV-1 CNS lymphoma, 12 patients with brain involvement of systemic HIV-1 NHL and 10 patients with systemic HIV-1 NHL without brain involvement. These were compared with HIV-1-infected patients with cerebral toxoplasmosis (19), progressive multifocal leukoencephalitis (PML; 8) and AIDS-related dementia (17) and with asymptomatic HIV-1 carriers (54) and uninfected individuals (50). The levels of sCD23 were compared with the presence of Epstein-Barr virus (EBV) DNA in CSF. Results: Significantly higher levels of sCD23 were found in the CSF of the patients with brain lymphoma than in those with systemic NHL (P <0.002) or with cerebral toxoplasmosis, PML and AIDS-related dementia (P <0.0001). The sensitivity and specificity of sCD23 in CSF as a marker for detection of brain NHL were 77% and 94%, respectively. High levels of sCD23 were found in CSF from patients with brain NHL independently of the presence (18 out of 26) or absence (8 out of 26) of EBV DNA. Conclusions: The sCD23 in CSF of HIV-1-infected patients may represent an additional, non-invasive marker for diagnosis of brain involvement in AIDS-related NHL.

Original languageEnglish
Pages (from-to)1109-1113
Number of pages5
JournalAIDS (London, England)
Volume15
Issue number9
DOIs
Publication statusPublished - Jun 15 2001

Fingerprint

AIDS-Related Lymphoma
Non-Hodgkin's Lymphoma
Cerebrospinal Fluid
HIV-1
Brain
Lymphoma
Cerebral Toxoplasmosis
Human Herpesvirus 4
Dementia
Acquired Immunodeficiency Syndrome
Central Nervous System
DNA
Enzyme-Linked Immunosorbent Assay

Keywords

  • AIDS
  • CD23
  • Cerebrospinal fluid
  • Epstein-Barr virus
  • Non-Hodgkin lymphoma
  • Plasma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Soluble CD23 in cerebrospinal fluid : A marker of AIDS-related non-Hodgkin's lymphoma in the brain. / Bossolasco, Simona; Nilsson, Anna; De Milito, Angelo; Lazzarin, Adriano; Linde, Annika; Cinque, Paola; Chiodi, Francesca.

In: AIDS (London, England), Vol. 15, No. 9, 15.06.2001, p. 1109-1113.

Research output: Contribution to journalArticle

Bossolasco, Simona ; Nilsson, Anna ; De Milito, Angelo ; Lazzarin, Adriano ; Linde, Annika ; Cinque, Paola ; Chiodi, Francesca. / Soluble CD23 in cerebrospinal fluid : A marker of AIDS-related non-Hodgkin's lymphoma in the brain. In: AIDS (London, England). 2001 ; Vol. 15, No. 9. pp. 1109-1113.
@article{478c406820694238a6247cf8905c9610,
title = "Soluble CD23 in cerebrospinal fluid: A marker of AIDS-related non-Hodgkin's lymphoma in the brain",
abstract = "Background: AIDS-related non-Hodgkin's lymphoma (NHL) includes systemic lymphomas, often with brain involvement, and primary central nervous system (CNS) lymphomas. Objective: To examine if measurement of soluble CD23 (sCD23) in cerebrospinal fluid (CSF) is useful in the diagnosis and follow-up of AIDS-related NHL. Method: sCD23 was measured by enzyme-linked immunosorbent assay and EBV DNA by nested polymerase chain reaction for a group of 134 patients. The NHL group included 14 patients with primary HIV-1 CNS lymphoma, 12 patients with brain involvement of systemic HIV-1 NHL and 10 patients with systemic HIV-1 NHL without brain involvement. These were compared with HIV-1-infected patients with cerebral toxoplasmosis (19), progressive multifocal leukoencephalitis (PML; 8) and AIDS-related dementia (17) and with asymptomatic HIV-1 carriers (54) and uninfected individuals (50). The levels of sCD23 were compared with the presence of Epstein-Barr virus (EBV) DNA in CSF. Results: Significantly higher levels of sCD23 were found in the CSF of the patients with brain lymphoma than in those with systemic NHL (P <0.002) or with cerebral toxoplasmosis, PML and AIDS-related dementia (P <0.0001). The sensitivity and specificity of sCD23 in CSF as a marker for detection of brain NHL were 77{\%} and 94{\%}, respectively. High levels of sCD23 were found in CSF from patients with brain NHL independently of the presence (18 out of 26) or absence (8 out of 26) of EBV DNA. Conclusions: The sCD23 in CSF of HIV-1-infected patients may represent an additional, non-invasive marker for diagnosis of brain involvement in AIDS-related NHL.",
keywords = "AIDS, CD23, Cerebrospinal fluid, Epstein-Barr virus, Non-Hodgkin lymphoma, Plasma",
author = "Simona Bossolasco and Anna Nilsson and {De Milito}, Angelo and Adriano Lazzarin and Annika Linde and Paola Cinque and Francesca Chiodi",
year = "2001",
month = "6",
day = "15",
doi = "10.1097/00002030-200106150-00005",
language = "English",
volume = "15",
pages = "1109--1113",
journal = "AIDS",
issn = "0269-9370",
publisher = "NLM (Medline)",
number = "9",

}

TY - JOUR

T1 - Soluble CD23 in cerebrospinal fluid

T2 - A marker of AIDS-related non-Hodgkin's lymphoma in the brain

AU - Bossolasco, Simona

AU - Nilsson, Anna

AU - De Milito, Angelo

AU - Lazzarin, Adriano

AU - Linde, Annika

AU - Cinque, Paola

AU - Chiodi, Francesca

PY - 2001/6/15

Y1 - 2001/6/15

N2 - Background: AIDS-related non-Hodgkin's lymphoma (NHL) includes systemic lymphomas, often with brain involvement, and primary central nervous system (CNS) lymphomas. Objective: To examine if measurement of soluble CD23 (sCD23) in cerebrospinal fluid (CSF) is useful in the diagnosis and follow-up of AIDS-related NHL. Method: sCD23 was measured by enzyme-linked immunosorbent assay and EBV DNA by nested polymerase chain reaction for a group of 134 patients. The NHL group included 14 patients with primary HIV-1 CNS lymphoma, 12 patients with brain involvement of systemic HIV-1 NHL and 10 patients with systemic HIV-1 NHL without brain involvement. These were compared with HIV-1-infected patients with cerebral toxoplasmosis (19), progressive multifocal leukoencephalitis (PML; 8) and AIDS-related dementia (17) and with asymptomatic HIV-1 carriers (54) and uninfected individuals (50). The levels of sCD23 were compared with the presence of Epstein-Barr virus (EBV) DNA in CSF. Results: Significantly higher levels of sCD23 were found in the CSF of the patients with brain lymphoma than in those with systemic NHL (P <0.002) or with cerebral toxoplasmosis, PML and AIDS-related dementia (P <0.0001). The sensitivity and specificity of sCD23 in CSF as a marker for detection of brain NHL were 77% and 94%, respectively. High levels of sCD23 were found in CSF from patients with brain NHL independently of the presence (18 out of 26) or absence (8 out of 26) of EBV DNA. Conclusions: The sCD23 in CSF of HIV-1-infected patients may represent an additional, non-invasive marker for diagnosis of brain involvement in AIDS-related NHL.

AB - Background: AIDS-related non-Hodgkin's lymphoma (NHL) includes systemic lymphomas, often with brain involvement, and primary central nervous system (CNS) lymphomas. Objective: To examine if measurement of soluble CD23 (sCD23) in cerebrospinal fluid (CSF) is useful in the diagnosis and follow-up of AIDS-related NHL. Method: sCD23 was measured by enzyme-linked immunosorbent assay and EBV DNA by nested polymerase chain reaction for a group of 134 patients. The NHL group included 14 patients with primary HIV-1 CNS lymphoma, 12 patients with brain involvement of systemic HIV-1 NHL and 10 patients with systemic HIV-1 NHL without brain involvement. These were compared with HIV-1-infected patients with cerebral toxoplasmosis (19), progressive multifocal leukoencephalitis (PML; 8) and AIDS-related dementia (17) and with asymptomatic HIV-1 carriers (54) and uninfected individuals (50). The levels of sCD23 were compared with the presence of Epstein-Barr virus (EBV) DNA in CSF. Results: Significantly higher levels of sCD23 were found in the CSF of the patients with brain lymphoma than in those with systemic NHL (P <0.002) or with cerebral toxoplasmosis, PML and AIDS-related dementia (P <0.0001). The sensitivity and specificity of sCD23 in CSF as a marker for detection of brain NHL were 77% and 94%, respectively. High levels of sCD23 were found in CSF from patients with brain NHL independently of the presence (18 out of 26) or absence (8 out of 26) of EBV DNA. Conclusions: The sCD23 in CSF of HIV-1-infected patients may represent an additional, non-invasive marker for diagnosis of brain involvement in AIDS-related NHL.

KW - AIDS

KW - CD23

KW - Cerebrospinal fluid

KW - Epstein-Barr virus

KW - Non-Hodgkin lymphoma

KW - Plasma

UR - http://www.scopus.com/inward/record.url?scp=0035876363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035876363&partnerID=8YFLogxK

U2 - 10.1097/00002030-200106150-00005

DO - 10.1097/00002030-200106150-00005

M3 - Article

VL - 15

SP - 1109

EP - 1113

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 9

ER -